Regeneron Pharmaceuticals today
Regeneron Pharmaceuticals
As of 02.27.2025 21:00
- 52-week range
- $ 642,00
▼
$ 1 211.20
- Dividend yield
- 0.13%
- P/e ratio.
- 18.36
- Value is valuable
- $ 973,13
Regeneron Pharmaceuticals Inc. Nasdak: Rain The stock remained relatively unnoticed by the main headlines in 2024, as GLP-1 manufacturers love Novo Nordisk a/s. NYSE: NVO And Eli Lilly & Co. NYSE: Lly He grabbed in the spotlight. Its shares closed by 18.9% in 2024.
The company also announced its first dividend in the world and allowed another 3 billion dollars in its ransom of shares. The shares decreased by 42% compared to the maximum in August 2024 in the amount of $ 1211.20. Investors who are looking for value (deep kickbacks) and growth (growth potential) may want to more and technically consider regeneron.
Dupixent earned $ 14 billion in 2024, but not all for Regeneron
As in the case of any large pharmaceutical company, this is all about current and future blockbuster, which are methods of treatment that bring sales of more than $ 1 billion. The best seller of Regeneron is dupixent, the treatment of symptoms of chronic inflammatory conditions caused by immune reactions of type 2. Dupixent is usually used for an average to a severe degree, chronic sinusitis with nasal and asthma polyps.
It works by blocking certain proteins in the immune system, which cause inflammation and help reduce symptoms, including itching, surpassed to the bosom and breathing difficulties. While regeneenerenon does not specifically produce vaccines, its monoclonal therapy of antibodies provides the effect of a “passive vaccine”, temporarily protecting from infections.
Dupixent can receive 30% more patients with the United States with approval of the expansion from FDA
Dupixent sales increased by 22% in 2024 to $ 14.15 billion. It was developed with Sanofi NASDAQ: NASWhich actually requires income and breaks down the profit from Regeneron. Regeneron publishes its part of Dupixent as income from cooperation. Regeneronon and Sanofi are striving to expand the use of Dupixent to include more conditions, including chronic obstructive lung disease (COPD), chronic spontaneous nettle (CSU) and bullet pemphigoid. Dupixent is used by one million patients around the world, and only COPD can add another 300,000 patients from the United States.
Ailea slows down, while Libtayo is the future blockbuster
Regeneron processing to the age degeneration of the yellow spot (AMD) Eylea and Eylea HD brought $ 5.9 billion. USA in 2024 in the United States. Eylea sales grew by only 1% year in 2024, since the growth of this blockbuster is slowing down. Regeneron has submitted regulatory applications to the FDA for the pre -filled Eylea HD syringe and had positive clinical tests of phase 3, which leads to the occlusion of the retinal veins (RVO). Libtayo sales in 2024 increased by 40% year to 1.22 billion dollars, which is its last blockbuster, which is just starting to accelerate. Libtayo received a positive phase 3 led to adjuvant plane cell carcinoma of high risk skin (CSCC).
Q4 results help to place below for regeneron shares
Forecast of pharmaceutical preparations Regeneronon Today Today
$ 973,13
38.47% growthModerate purchase
Based on 25 analysts ratings
| High forecast | $ 1300.00 |
|---|---|
| Average forecast | $ 973,13 |
| Low forecast | $ 165.00 |
Regeneron pharmaceuticals Fundage data forecast
Regeneron announced 4024 in Q424 in the amount of $ 12.07, exceeding the consensus estimates by 71 centers. Revenue increased by 10.3% year to $ 3.79 billion. The United States, having beaten the consensus estimates of $ 3.74 billion. USA. Pure income without GAAP increased by 2% to 1.39 billion dollars. USA. The income from Sanofi cooperation for 2024 increased to $ 3.924 billion, compared with $ 3.127 billion. The board of directors initiated its first dividend in the amount of 88 cents. The board also expanded its redemption program for an additional $ 3 billion, as a result of which the total amount of up to $ 4.5 billion.
The company led 2025 gross profit for the sale of clean products from 87% to 88%. Non -Ocr from 5.5 to 5.2 billion dollars. USA, and capital costs from 850 to 975 million dollars. USA.
General Director of Regeneron Dr. Leonard Schleifer added: “In 2025, we will continue to focus on our four blockbuster of the medicine, since we are promoting our approximately 40 candidates for research covering dozens of painful conditions with extensive market potential.”
REGN Stock is trying to make a cup
A sample of a cup and handle consists of a rounded cup, followed by a shallow rolling of a handle. The cup forms when the action decreases from the peak to swing, rounds and rallies to re -check the previous maximum. A brief rollback from this high creates a pen, and the breakthrough is signaling when the action finally exceeds this level during the subsequent course.
The regun formed his daily lip cup at a swing height at the level of $ 800.99 on December 9, 2024, and then plunged up to three years of swing at 641.66 US dollars. The regun left the spiral from the minimums in a solid report on income for 4 quarter, as he is trying to complete the rounding of the bottom over the daily, an $ 691.03. Daily RSI slowly rises after 55-Bal. Fibonacci (FIB) The pumping support levels are $ 666.25, 641.66 US dollars, $ 614.28 and $ 575.49.
The average consensus target price REGN is 38.95% higher at 973.13 US dollars, and its highest target price of analysts costs $ 1300. He has 18 purchases of purchase 18 analysts, six holds and one sales rating. Promotions have 2% short percentage.
Bull investors can consider the possibility of using cash, at the levels of FIB rollback to buy DIP. In the case of the appointment of shares, then writing covered calls at the levels of increasing FIB performs a wheel strategy for income in addition to a recently initiated dividend of 0.13%.
Before considering Regeneron Pharmaceuticals, you will want to hear this.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market was stuck on … and Regeneron Pharmaceuticals was not on the list.
While Regeneron Pharmaceuticals currently has a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Due to the distribution of data processing and electric vehicles, the electric grid will only be more intense. Download this report to find out how energy shares can play a role in your portfolio, since global energy demand continues to grow.
Get this free report